Form 4: Tvardi Therapeutics Director Acquires Stock Options

Director Sujal Shah of Tvardi Therapeutics acquires stock options exercisable for 12,000 shares of common stock.

Summary

• Sujal Shah, a director of Tvardi Therapeutics, acquired stock options on April 17, 2025.
• The options grant the right to purchase 12,000 shares of Tvardi Therapeutics common stock at an exercise price of $17.04 per share.
• The options vest in 12 equal quarterly installments over three years, starting on July 17, 2025, contingent upon continuous service.
• The options expire on April 16, 2035.
• Following the transaction, Shah directly owns options exercisable for 12,000 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director generally indicates confidence in the company's future, but it's a routine transaction.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule indicates a three-year commitment from the director, suggesting a long-term perspective on the company's prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. This filing indicates a standard compensation practice of granting stock options to directors.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the biotechnology industry to align their interests with those of shareholders.
• The vesting schedule of three years is also typical for such grants.

Stakeholder Impact

• The acquisition of stock options by a director can positively influence shareholder sentiment.

Key Dates

Keywords

Tvardi Therapeutics, Stock Options, Director, Beneficial Ownership, Form 4, TVRD, Sujal Shah